Prot #MK-3222-010: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Mo

  • Gordon, Kenneth B (PD/PI)

Project: Research project

Project Details

Effective start/end date8/26/138/26/16


  • Parexel (Prot #MK-3222-010 // Prot #MK-3222-010)
  • Merck Sharp & Dohme Corporation (Prot #MK-3222-010 // Prot #MK-3222-010)